Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows

Teladoc Health (NYSE: TDOC - Get Free Report) and National Research (NASDAQ: NRC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares Teladoc

Teladoc (TDOC) reached $5.75 at the closing of the latest trading day, reflecting a -2.38% change compared to its last close.

Corient Private Wealth LP trimmed its holdings in shares of Teladoc Health, Inc. (NYSE: TDOC) by 62.8% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 101,556 shares of the health services provider's stock after selling 171,447 shares during the period. Corient Private Wealth LP owned

Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026

Teladoc (TDOC) closed the most recent trading day at $6.13, moving 3.46% from the previous trading session.

Teladoc (TDOC) concluded the recent trading session at $6.28, signifying a -2.33% move from its prior day's close.

Teladoc Health trades near multi-year lows, with the market pricing in deep distress despite meaningful free cash flow and manageable debt. BetterHelp's rapid decline drags on TDOC, but Integrated Care's improving margins and growing revenue per member offer stabilization. TDOC's valuation is extremely depressed, trading at just 7–8x expected free cash flow, with fair value estimates suggesting significant upside even under conservative scenarios.

Teladoc (TDOC) reached $6.16 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.